VX-222 Lomibuvir cas 1026785-59-0

Lomibuvir, also known as VX-222, VCH-222 and VX22, is an nonnucleoside NS5B polymerase inhibitor. VX-222 inhibits the 1b/Con1 HCV subgenomic replicon, with 50% effective concentrations (EC(50)s) 5 nM. VX-222 binds to the HCV polymerase with dissociation constants of 17 nM. In phase 1 and 2 clinical studies, VX-222 demonstrated effective antiviral efficacy, with substantial reductions in plasma HCV RNA in patients chronically infected with genotype 1 HCV.

HCV Protease Inhibitors Related Prodcuts:

Daclatasvir; Daclatasvir hcl; Telaprevir; Danoprevir; Paritaprevir; Paritaprevir dihydrate; Grazoprevir; Elbasvir; Ombitasvir; Simeprevir; Velpatasvir; Ledipasvir; Boceprevir

[1]. Yi G, Deval J, Fan B, Cai H, Soulard C, Ranjith-Kumar CT, Smith DB, Blatt L, Beigelman L, Kao CC.Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.Antimicrob Agents Chemother. 2012 Feb;56(2):830-7.

[2]. Godzik P, Komorowski M, Cielecka-Kuszyk J, Madaliński K.[Inhibitors of hepatitis C virus--current standards and status of investigations].Przegl Epidemiol. 2010;64(4):473-8.